Specific MUC1 splice variants are correlated with tumor progression in esophageal cancer

World Journal of Surgery

Volumn 38, Issue 8, 2014, Pages 2052-2057

  Kahkhaie, Kolsoum Rezaie ^a,e   Moaven, Omeed ^b   Abbaszadegan, Mohammad Reza ^c   Montazer, Mehdi ^d   Gholamin, Mehran ^c  

^a PAYAME NOOR UNIVERSITY   (Iran)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e ZABOL UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ISOPROTEIN; MESSENGER RNA; MUCIN 1; RNA; TUMOR MARKER; TUMOR PROTEIN;

AGED; ALTERNATIVE RNA SPLICING; DISEASE COURSE; ESOPHAGUS TUMOR; FEMALE; GENETICS; HUMAN; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SQUAMOUS CELL CARCINOMA;

AGED; ALTERNATIVE SPLICING; CARCINOMA, SQUAMOUS CELL; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; MUCIN-1; NEOPLASM PROTEINS; PROGNOSIS; PROTEIN ISOFORMS; RNA, MESSENGER; RNA, NEOPLASM; TUMOR MARKERS, BIOLOGICAL;

EID: 84903755595     PISSN: 03642313     EISSN: 14322323     Source Type: Journal    
DOI: 10.1007/s00268-014-2523-1     Document Type: Article

References (30)

1. Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24:2137-2150 (Pubitemid 46655601)
2. Cloosen S, Gratama J, van Leeuwen EB et al (2006) Cancer specific mucin-1 glycoforms are expressed on multiple myeloma. Br J Haematol 135:513-516 (Pubitemid 44583416)
3. Guillem P, Billeret V, Buisine MP et al (2000) Mucin gene expression and cell differentiation in human normal, premalignant and malignant esophagus. Int J Cancer 88:856-861
4. Song ZB, Gao SS, Yi XN et al (2003) Expression of MUC1 in esophageal squamous-cell carcinoma and its relationship with prognosis of patients from Linzhou City, a high incidence area of northern China. World J Gastroenterol 9:404-407
5. Obermair A, Schmid BC, Packer LM et al (2002) Expression of MUC1 splice variants in benign and malignant ovarian tumours. Int J Cancer 100:166-171 (Pubitemid 34666190)
6. Imbert-Fernandez Y, Radde BN, Teng Y et al (2011) MUC1/A and MUC1/B splice variants differentially regulate inflammatory cytokine expression. Exp Eye Res 93:649-657
7. Ilkovitch D, Lopez DM (2009) Urokinase-mediated recruitment of myeloid-derived suppressor cells and their suppressive mechanisms are blocked by MUC1/SEC. Blood 113:4729-4839
8. Schmid BC, Rudas M, Fabjani G et al (2003) Evaluation of MUC1 splice variants as prognostic markers in patients with ductal carcinoma in situ of the breast. Oncol Rep 10:1981-1985
9. Schut IC, Waterfall PM, Ross M et al (2003) MUC1 expression, splice variant and short form transcription (MUC1/Z, MUC1/Y) in prostate cell lines and tissue. BJU Int 91:278-283 (Pubitemid 36232850)
10. Zhang L, Vlad A, Milcarek C et al (2013) Human mucin MUC1 RNA undergoes different types of alternative splicing resulting in multiple isoforms. Cancer Immunol Immunother 62:423-435
11. Taylor-Papadimitriou J, Burchell J, Miles DW et al (1999) MUC1 and cancer. Biochim Biophys Acta 1455:301-313 (Pubitemid 29435996)
12. Wei X, Xu H, Kufe D (2005) Human MUC1 oncoprotein regulates p53-responsive gene transcription in the genotoxic stress response. Cancer Cell 7:167-178 (Pubitemid 40248342)
13. Ren J, Li Y, Kufe D (2002) Protein kinase C delta regulates function of the DF3/MUC1 carcinoma antigen in beta-catenin signaling. J Biol Chem 277:17616-17622 (Pubitemid 34967564)
14. Ghosh SK, Pantazopoulos P, Medarova Z et al (2013) Expression of underglycosylated MUC1 antigen in cancerous and adjacent normal breast tissues. Clin Breast Cancer 13:109-118
15. Saeland E, Belo AI, Mongera S et al (2012) Differential glycosylation of MUC1 and CEACAM5 between normal mucosa and tumour tissue of colon cancer patients. Int J Cancer 131:117-128
16. Remmers N, Anderson JM, Linde EM et al (2013) Aberrant expression of mucin core proteins and o-linked glycans associated with progression of pancreatic cancer. Clin Cancer Res 19:1981-1993
17. Ye Q, Yan Z, Liao X et al (2011) MUC1 induces metastasis in esophageal squamous cell carcinoma by upregulating matrix metalloproteinase 13. Lab Investig 91:778-787
18. Sun ZG, Wang Z, Liu XY et al (2011) Mucin 1 and vascular endothelial growth factor C expression correlates with lymph node metastatic recurrence in patients with N0 esophageal cancer after Ivor-Lewis esophagectomy. World J Surg 35:70-77. doi: 10.1007/s00268-010-0829-1
19. Chen H, Wang Z, Yang Z et al (2013) Prospective study of adjuvant radiotherapy on preventing lymph node metastasis after Ivor-Lewis esophagectomy in esophageal cancer. Ann Surg Oncol 20:2721-2726
20. Sun ZG, Wang Z (2011) Clinical study on lymph node metastatic recurrence in patients with N0 esophageal squamous cell cancer. Dis Esophagus 24:182-188
21. Brockhausen I (1999) Pathways of O-glycan biosynthesis in cancer cells. Biochim Biophys Acta 1473:67-95
22. Brockhausen I, Yang JM, Burchell J et al (1995) Mechanisms underlying aberrant glycosylation of MUC1 mucin in breast cancer cells. Eur J Biochem 233:607-617
23. Matsushita T, Ohyabu N, Fujitani N et al (2013) Site-specific conformational alteration induced by sialylation of MUC1 tandem repeating glycopeptides at an epitope region for the anti-KL-6 monoclonal antibody. Biochemistry 52:402-414
24. Ramasamy S, Duraisamy S, Barbashov S et al (2007) The MUC1 and galectin-3 oncoproteins function in a microRNA-dependent regulatory loop. Mol Cell 27:992-1004 (Pubitemid 47488189)
25. Raina D, Kosugi M, Ahmad R et al (2011) Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells. Mol Cancer Ther 10:806-816
26. Senapati S, Das S, Batra SK (2010) Mucin-interacting proteins: from function to therapeutics. Trends Biochem Sci 35:236-245
27. Germain RN (1994) MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell 76:287-299
28. Becker T, Dziadek S, Wittrock S et al (2006) Synthetic glycopeptides from the mucin family as potential tools in cancer immunotherapy. Curr Cancer Drug Targets 6:491-517 (Pubitemid 44371971)
29. Acres B, Limacher JM (2005) MUC1 as a target antigen for cancer immunotherapy. Expert Rev Vaccines 4:493-502 (Pubitemid 41297296)
30. Cai H, Sun ZY, Huang ZH et al (2013) Fully synthetic self-adjuvanting thioether-conjugated glycopeptide-lipopeptide antitumor vaccines for the induction of complement-dependent cytotoxicity against tumor cells. Chemistry 19:1962-1970